CTXR logo

CTXR
Citius Pharmaceuticals Inc

21,598
Mkt Cap
$19.4M
Volume
130,890.00
52W High
$5.95
52W Low
$0.65
PE Ratio
-0.21
CTXR Fundamentals
Price
$1.03
Prev Close
$1.05
Open
$1.04
50D MA
$1.29
Beta
1.21
Avg. Volume
588,246.32
EPS (Annual)
-$5.97
P/B
0.23
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules Citius Oncology Announces Closing of $18 Million...
PR Newswire·13d ago
News Placeholder
More News
News Placeholder
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules Citius Oncology Announces $18 Million Concurrent Registered...
PR Newswire·14d ago
News Placeholder
Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East...
PR Newswire·19d ago
News Placeholder
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel...
PR Newswire·22d ago
News Placeholder
Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration
Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration PR Newswire CRANFORD, N.J., Nov...
PR Newswire·1mo ago
News Placeholder
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces the Closing of Registered Direct...
PR Newswire·2mo ago
News Placeholder
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million...
PR Newswire·2mo ago
News Placeholder
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences PR...
PR Newswire·2mo ago
News Placeholder
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to...
PR Newswire·2mo ago
<
...
1
>

Latest CTXR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.